Target intelligence / Profile preview

Glutamic acid (Glu (or E))

Target
Glu (or E)
Molecular classification
Amino acid, Neurotransmitter (as glutamate)
01

Overview

Glutamic acid is a non-essential amino acid, meaning humans can synthesize it de novo.[2][7][9] It consists of an α-amino group, an α-carboxyl group, and a distinctive side chain terminating in a carboxylic acid, giving it acidic properties at physiological pH.[1][5][7] In proteins and metabolic pathways, it fulfills crucial roles as a metabolic intermediate and as the most abundant excitatory neurotransmitter in the brain (in the form of glutamate), mediating synaptic transmission essential to cognition, memory, and learning.[4][6][8] It is also important in nitrogen disposal (via the urea cycle), as a precursor to other amino acids, and in the regulation of cellular redox state via glutathione production. Although central to neurobiology, energy metabolism, and cellular function, glutamic acid itself is not a typical therapeutic "target"—therapies usually target glutamate receptors, transporters, or enzymes that act on or regulate glutamate[3][4][6][7][8].

Other names
glutamateL-glutamic acidα-aminoglutaric acidE (one-letter code)Glu (three-letter code)
02

Mechanism of action

Not applicable for glutamic acid itself; clinically, drugs may modulate glutamate receptors or transport, not the amino acid directly.

03

Biological functions

Precursor in protein synthesisMajor excitatory neurotransmitter in the central nervous system (as glutamate)Intermediate in ammonia detoxificationSubstrate in cellular metabolism and energy productionPrecursor for biosynthesis of glutamine, proline, and arginine
04

Disease associations

Imbalance linked to certain neurological disorders (e.g., epilepsy, excitotoxicity, neurodegenerative diseases)Tumor metabolism in certain brain cancers
05

Safety considerations

Excess supplementation may cause metabolic disturbances or acid-base imbalance (systemic acidosis)Neurotoxicity in the context of glutamate excitotoxicityNot recommended in certain metabolic disorders (e.g., maple syrup urine disease, cystinuria)
06

Biomarkers

Elevated or reduced glutamic acid/glutamate levels may be used in neurological disease research or metabolic disorders, but glutamic acid is not an established clinical biomarker for therapy selection or monitoring.

Beyond the preview

Go deeper on Glutamic acid (Glu (or E)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glutamic acid (Glu (or E)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call